ID

DB00258|APRD00839||

名称

Calcium acetate

描述

The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.

cas号

62-54-4

唯一标识码

Y882YXF34X

状态

solid

组

approved,investigational,

指示

Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

药效学

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

作用机制

Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.

毒性

Oral, rat: LD₅₀ = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

代谢

吸收

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

半衰期

分类

description:This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
direct-parent:Carboxylic acids
kingdom:Organic compounds
superclass:Organic acids and derivatives
class:Carboxylic acids and derivatives
subclass:Carboxylic acids
alternative-parent:Carbonyl compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organic salts
substituent:Aliphatic acyclic compound
substituent:Carbonyl group
substituent:Carboxylic acid
substituent:Hydrocarbon derivative
substituent:Monocarboxylic acid or derivatives
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organic salt
substituent:Organooxygen compound

消除途径

Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.

种类

Acids
D000143
Acids, Acyclic
D000144
Acids, Noncarboxylic
D000148
Alimentary Tract and Metabolism

Arylsulfonates
D001190
Arylsulfonic Acids
D017739
Benzene Derivatives
D001555
Blood Coagulation Factors
D001779
Calcium Salts
D002118
Chelating Agents
D002614
Compounds used in a research, industrial, or household setting
D020313
Drugs for Treatment of Hyperkalemia and Hyperphosphatemia

Fatty Acids
D005227
Fatty Acids, Volatile
D005232
Lipids
D008055
Minerals
D008903
Phosphate Binder

Phosphate-removing Agents

Sequestering Agents
D064449
Sulfonic Acids
D013451
Sulfur Acids
D013456
Sulfur Compounds
D013457

盐类

DBSALT001536Calcium acetate monohydrate7ZA48GIM5H5743-26-0XQKKWWCELHKGKB-UHFFFAOYSA-L176.181175.9997643

蛋白质结合

清除

同义词

language:english; code:; name;Acetate of lime
language:english; code:; name;Brown acetate of lime
language:spanish; code:; name;Calcio acetato
language:english; code:jan/usp; name;Calcium acetate
language:english; code:; name;calcium ethanoate
language:english; code:; name;calcium(II) acetate
language:english; code:; name;Gray acetate of lime
language:english; code:; name;Lime acetate
language:english; code:; name;Lime pyrolignite

国际品牌

PhosloTeltozan

配送量

产品

name:Aluminum Acetate Astringent
labeller:Epic Pharma, LLC
ndc-id:
ndc-product-code:42806-106
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-28
ended-marketing-on:2013-04-30
dosage-form:Powder, for solution
strength:
route:Topical
fda-application-number:part347
generic:false
over-the-counter:true
approved:false
country:US
source:FDA NDC
name:Aluminum Acetate Astringent
labeller:Tagi Pharma Incorporated
ndc-id:
ndc-product-code:51224-153
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-15
ended-marketing-on:
dosage-form:Powder, for solution
strength:
route:Topical
fda-application-number:part347
generic:false
over-the-counter:true
approved:false
country:US
source:FDA NDC
name:Astringent
labeller:TAGI Pharma Inc.
ndc-id:
ndc-product-code:51224-162
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-01
ended-marketing-on:
dosage-form:Powder, for solution
strength:
route:Topical
fda-application-number:part347
generic:false
over-the-counter:true
approved:false
country:US
source:FDA NDC
name:Calcium Acetate
labeller:State of Florida DOH Central Pharmacy
ndc-id:
ndc-product-code:53808-0216
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Atlantic Biologicals Corps.
ndc-id:
ndc-product-code:17856-0088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:State of Florida DOH Central Pharmacy
ndc-id:
ndc-product-code:53808-0905
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Camber Pharmaceuticals
ndc-id:
ndc-product-code:31722-393
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-03
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA202420
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Camber Pharmaceuticals
ndc-id:
ndc-product-code:31722-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-03
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:State of Florida DOH Central Pharmacy
ndc-id:
ndc-product-code:53808-1001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Zydus Pharmaceuticals Usa, Inc.
ndc-id:
ndc-product-code:68382-642
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-23
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA202885
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Zydus Pharmaceuticals Usa, Inc.
ndc-id:
ndc-product-code:68382-539
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-07
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202315
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-064
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-11
ended-marketing-on:2011-11-12
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Lupin Pharmaceuticals
ndc-id:
ndc-product-code:57297-134
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-09-09
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202127
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-2303
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Hikma Pharmaceuticals USA Inc.
ndc-id:
ndc-product-code:0054-0088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Atlantic Biologicals Corps.
ndc-id:
ndc-product-code:17856-0377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-03
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0621
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-02-23
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA202885
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-280
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:2017-09-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6668
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-07
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202315
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6546
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-08
ended-marketing-on:2020-12-31
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Doh Central Pharmacy
ndc-id:
ndc-product-code:53808-1103
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-19
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Paddock Laboratories, LLC
ndc-id:
ndc-product-code:0574-0113
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-09-13
ended-marketing-on:2020-10-31
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA091561
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-134
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-20
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202127
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:ECI Pharmaceuticals, LLC
ndc-id:
ndc-product-code:51293-825
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-25
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203298
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Chartwell RX LLC
ndc-id:
ndc-product-code:62135-192
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-01
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA202420
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2231
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-23
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203179
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:65162-590
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-08
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1351
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Lotus Pharmaceutical Co., Ltd. Nantou Plant
ndc-id:
ndc-product-code:40051-049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-09-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203298
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2372
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-10-21
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Fresenius Medical Care North America
ndc-id:
ndc-product-code:49230-644
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/667mg
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Marlex Pharmaceuticals Inc
ndc-id:
ndc-product-code:10135-629
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203298
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Nostrum Laboratories, Inc.
ndc-id:
ndc-product-code:29033-026
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203179
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-491
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203179
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8090
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-08
ended-marketing-on:2021-10-31
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:AvKARE, Inc.
ndc-id:
ndc-product-code:42291-189
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-15
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0172
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0529
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:AvPAK
ndc-id:
ndc-product-code:50268-148
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-16
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Suven Life Sciences Ltd
ndc-id:
ndc-product-code:68022-0119
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-10
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA211038
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
ndc-id:
ndc-product-code:23155-621
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-22
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA202885
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Precision Dose, Inc.
ndc-id:
ndc-product-code:68094-002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-08-22
ended-marketing-on:2021-06-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Exelan Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:76282-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-14
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Cipla USA Inc.,
ndc-id:
ndc-product-code:69097-862
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Chartwell Rx, Llc.
ndc-id:
ndc-product-code:62135-191
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-29
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA091312
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0772
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-09
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202127
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Apnar Pharma
ndc-id:
ndc-product-code:24689-793
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-06
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA211038
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2723
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-05-04
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA091312
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Atlantic Biologicals Corp.
ndc-id:
ndc-product-code:17856-0191
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-29
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA091312
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7880
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-08
ended-marketing-on:2020-12-31
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4984
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-07-26
ended-marketing-on:2021-06-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
ndc-id:
ndc-product-code:23155-531
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-07
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202315
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-2081
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-2672
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Safecor Health, LLC
ndc-id:
ndc-product-code:48433-300
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-15
ended-marketing-on:2019-11-11
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA091561
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0621
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-08
ended-marketing-on:2019-09-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4961
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:2016-11-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Clinical Solutions Wholesale
ndc-id:
ndc-product-code:58118-2081
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2018-10-30
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0521
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-15
ended-marketing-on:2017-05-24
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA202127
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-7210
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-26
ended-marketing-on:2018-10-31
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203179
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1277
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-25
ended-marketing-on:2020-04-28
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA201658
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-09
ended-marketing-on:2017-05-24
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-479
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-07-26
ended-marketing-on:2022-01-31
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA077728
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8364
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-26
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:ANDA203135
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Calcium Acetate 667 mg
labeller:Pharmin USA, LLC
ndc-id:
ndc-product-code:70586-1347
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-02-26
ended-marketing-on:
dosage-form:Tablet, coated
strength:667 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Calcium Acetate Tab 667mg
labeller:Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.
ndc-id:
ndc-product-code:
dpd-id:01982591
ema-product-code:
ema-ma-number:
started-marketing-on:1993-12-31
ended-marketing-on:2002-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:true
approved:true
country:Canada
source:DPD
name:Calphron
labeller:Nephro-Tech, Inc.
ndc-id:
ndc-product-code:59528-0331
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-04-01
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Domeboro
labeller:Advantice Health, LLC.
ndc-id:
ndc-product-code:16864-240
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-26
ended-marketing-on:
dosage-form:Powder, for solution
strength:
route:Topical
fda-application-number:part347
generic:false
over-the-counter:true
approved:false
country:US
source:FDA NDC
name:Eliphos
labeller:Carilion Materials Management
ndc-id:
ndc-product-code:68151-5204
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-02-01
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA078502
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Eliphos
labeller:Kaiser Foundations Hospitals
ndc-id:
ndc-product-code:0179-0098
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-24
ended-marketing-on:2013-08-31
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA078502
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Eliphos
labeller:Hawthorn Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:63717-910
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-02-01
ended-marketing-on:2017-10-01
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:ANDA078502
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Hyperlyte (multi-electrolyte Concentrate)
labeller:B. Braun Medical Inc.
ndc-id:
ndc-product-code:
dpd-id:01963910
ema-product-code:
ema-ma-number:
started-marketing-on:1998-09-04
ended-marketing-on:2017-07-15
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lypholyte
labeller:Partners Health Care, Inc.
ndc-id:
ndc-product-code:
dpd-id:02139618
ema-product-code:
ema-ma-number:
started-marketing-on:1996-08-14
ended-marketing-on:2008-01-10
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lypholyte Multi-electrolyte Conc Inj
labeller:Lyphomed, Division Of Fujisawa Canada Inc.
ndc-id:
ndc-product-code:
dpd-id:01944940
ema-product-code:
ema-ma-number:
started-marketing-on:1991-12-31
ended-marketing-on:1996-09-10
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nutrilyte
labeller:American Regent
ndc-id:
ndc-product-code:0517-3120
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1990-09-30
ended-marketing-on:2013-05-08
dosage-form:Injection, solution, concentrate
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Phoslo
labeller:Nabi Biopharmaceuticals
ndc-id:
ndc-product-code:59730-6402
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-01
ended-marketing-on:2007-06-14
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Phoslo
labeller:Nabi Biopharmaceuticals
ndc-id:
ndc-product-code:59730-6401
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-01
ended-marketing-on:
dosage-form:Tablet
strength:667 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Phoslo
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5691
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-01
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Phoslo
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3460
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1997-08-27
ended-marketing-on:2006-10-11
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:PhosLo
labeller:Fresenius Medical Care North America
ndc-id:
ndc-product-code:49230-640
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-04-02
ended-marketing-on:
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Phoslo
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7750
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-04-02
ended-marketing-on:2012-02-29
dosage-form:Capsule
strength:667 mg/1
route:Oral
fda-application-number:NDA021160
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Phoslo Tablets
labeller:Fresenius Medical Care North America
ndc-id:
ndc-product-code:
dpd-id:02229437
ema-product-code:
ema-ma-number:
started-marketing-on:2006-02-22
ended-marketing-on:2013-07-29
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Phoslyra
labeller:Fresenius Medical Care North America
ndc-id:
ndc-product-code:49230-643
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-04-15
ended-marketing-on:
dosage-form:Solution
strength:667 mg/5mL
route:Oral
fda-application-number:NDA022581
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ProcalAmine
labeller:B. Braun Medical Inc.
ndc-id:
ndc-product-code:0264-1915
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1982-05-06
ended-marketing-on:
dosage-form:Injection
strength:
route:Intravenous
fda-application-number:NDA018582
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Phoslo
ingredients:Calcium acetate
name:Phoslo
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Phoslo
ingredients:Calcium acetate
name:Phoslo
ingredients:Calcium acetate
name:Aluminum Acetate Astringent
ingredients:Aluminum sulfate + Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Eliphos
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Eliphos
ingredients:Calcium acetate
name:Eliphos
ingredients:Calcium acetate
name:Nutrilyte
ingredients:Calcium acetate + Gluconic Acid + Magnesium acetate + Potassium acetate + Potassium chloride + Sodium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Aluminum Acetate Astringent
ingredients:Aluminum sulfate + Calcium acetate
name:Astringent
ingredients:Aluminum sulfate + Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calphron
ingredients:Calcium acetate
name:Calcium Acetate 667 mg
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:PhosLo
ingredients:Calcium acetate
name:Phoslyra
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Domeboro
ingredients:Aluminum sulfate + Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:ProcalAmine
ingredients:Alanine + Arginine + Calcium acetate + Cysteine + Glycerin + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium acetate + Methionine + Phenylalanine + Phosphoric acid + Potassium chloride + Proline + Serine + Sodium acetate + Sodium chloride + Threonine + Tryptophan + Valine
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Phoslo
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate
ingredients:Calcium acetate
name:Calcium Acetate Tab 667mg
ingredients:Calcium acetate
name:Lypholyte Multi-electrolyte Conc Inj
ingredients:Calcium acetate + Gluconic Acid + Magnesium acetate + Potassium acetate + Potassium chloride + Sodium acetate
name:Lypholyte
ingredients:Calcium acetate + Gluconic Acid + Magnesium acetate + Potassium acetate + Potassium chloride + Sodium acetate
name:Phoslo Tablets
ingredients:Calcium acetate
name:Hyperlyte (multi-electrolyte Concentrate)
ingredients:Calcium acetate + Gluconic Acid + Magnesium acetate + Potassium acetate + Potassium chloride + Sodium acetate

包装者

name:Biotest Pharmaceuticals
url:http://www.biotestpharma.com
name:Braintree Laboratories Inc.
url:http://www.braintreelabs.com
name:Hawthorn Pharmaceuticals
url:http://www.hawthornrx.com
name:Kaiser Foundation Hospital
url:
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Roxane Labs
url:http://www.roxane.com
name:Stason Pharmaceuticals Inc.
url:http://www.stasonpharma.com
name:Tya Pharmaceuticals
url:
name:Vangard Labs Inc.
url:

生产者

generic:是; url:; name;Roxane laboratories inc
generic:否; url:; name;Fresenius medical care north america
generic:否; url:; name;Cypress pharmaceutical inc

价格

PhosLo 667 mg capsule
1.05(单位：USD）
capsule
Phoslo 667 mg tablet
0.41(单位：USD）
tablet

受影响的生物体

Humans and other mammals

剂量

form:Lotion
route:Topical
strength:0.118 g
form:Powder
route:Topical
strength:36.45 mg
form:Lotion
route:Topical
strength:0.059 g
form:Powder, for solution
route:Topical
strength:
form:Tablet
route:Oral
strength:700 mg
form:Tablet, film coated
route:Oral
strength:475 mg/1
form:Tablet, coated
route:Oral
strength:1 g
form:Tablet, coated
route:Oral
strength:667 mg
form:Capsule
route:Oral
strength:667 mg/667mg
form:Tablet, coated
route:Oral
strength:667 mg/1
form:Tablet
route:Oral
strength:
form:Tablet, film coated
route:Oral
strength:475 MG
form:Tablet, film coated
route:Oral
strength:950 MG
form:Tablet, film coated
route:Oral
strength:500 mg
form:Tablet, film coated
route:Oral
strength:500 mg/1
form:Tablet, film coated
route:Oral
strength:700 mg/1
form:Tablet, film coated
route:Oral
strength:950 mg/1
form:Powder
route:Topical
strength:36.45 g
form:Tablet, film coated
route:Oral
strength:1000 mg
form:Tablet, film coated
route:Oral
strength:700 mg
form:Lotion
route:Topical
strength:0.59 g
form:Solution
route:Intravenous
strength:
form:Liquid
route:Intravenous
strength:
form:Injection, solution, concentrate
route:Intravenous
strength:
form:Tablet, coated
route:Oral
strength:435 mg
form:Tablet, film coated
route:Oral
strength:435 mg
form:Injection, solution
route:Intravenous
strength:3 g/100ml
form:Tablet
route:Oral
strength:250 mg
form:Tablet
route:Oral
strength:1000 mg
form:Tablet
route:Oral
strength:667 mg
form:Capsule
route:Oral
strength:667 mg/1
form:Capsule
route:Oral
strength:667 MG
form:Tablet
route:Oral
strength:667 mg/1
form:Solution
route:Oral
strength:667 mg/5mL
form:Tablet, coated
route:Oral
strength:90 mg
form:Injection
route:Intravenous
strength:
form:Solution
route:Parenteral
strength:3 g/100ml
form:Capsule, coated
route:Oral
strength:500 mg

atc代码

Drugs for treatment of hyperkalemia and hyperphosphatemia
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
VARIOUS
Ascorbic acid (vitamin C), combinations
ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS
VITAMINS
ALIMENTARY TRACT AND METABOLISM
Drugs for treatment of hyperkalemia and hyperphosphatemia
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
VARIOUS

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00258.pdf?1265922814

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00258.pdf?1265922750

专利

number:6576665
country:United States
approved:2003-06-10
expires:2021-04-03
pediatric-extension:否
number:6875445
country:United States
approved:2005-04-05
expires:2021-07-30
pediatric-extension:否
number:8591938
country:United States
approved:2013-11-26
expires:2030-02-23
pediatric-extension:否
number:8592480
country:United States
approved:2013-11-26
expires:2027-07-20
pediatric-extension:否
number:9089528
country:United States
approved:2015-07-28
expires:2027-07-20
pediatric-extension:否

食物相互作用

Take with food. When taken with food, calcium acetate forms an insoluble complex with the phosphorus from food, reducing phosphorus serum concentrations.

药物相互作用

DB00218
Calcium acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00365
Calcium acetate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00467
Calcium acetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00487
Calcium acetate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00537
Calcium acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00685
Calcium acetate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00779
Calcium acetate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00817
Calcium acetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00827
Calcium acetate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00978
Calcium acetate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01044
Calcium acetate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01059
Calcium acetate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01137
Calcium acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01155
Calcium acetate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01165
Calcium acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01208
Calcium acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01405
Calcium acetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB04576
Calcium acetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB05488
Calcium acetate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06160
Calcium acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06600
Calcium acetate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08972
Calcium acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11404
Calcium acetate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11443
Calcium acetate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11491
Calcium acetate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11511
Calcium acetate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11774
Calcium acetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11892
Calcium acetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11943
Calcium acetate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13261
Calcium acetate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13627
Calcium acetate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13772
Calcium acetate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13823
Calcium acetate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01212
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Ceftriaxone.
DB08826
The serum concentration of Deferiprone can be decreased when it is combined with Calcium acetate.
DB00841
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium acetate.
DB08930
The serum concentration of Dolutegravir can be decreased when it is combined with Calcium acetate.
DB06210
The serum concentration of Eltrombopag can be decreased when it is combined with Calcium acetate.
DB01196
Calcium acetate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00326
The risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Calcium acetate.
DB01164
The risk or severity of adverse effects can be increased when Calcium chloride is combined with Calcium acetate.
DB01373
The risk or severity of adverse effects can be increased when Calcium is combined with Calcium acetate.
DB06724
The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcium acetate.
DB11093
The risk or severity of adverse effects can be increased when Calcium citrate is combined with Calcium acetate.
DB11126
The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcium acetate.
DB11348
The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Calcium acetate.
DB13142
The risk or severity of adverse effects can be increased when Calcium glubionate anhydrous is combined with Calcium acetate.
DB13231
The risk or severity of adverse effects can be increased when Calcium lactate is combined with Calcium acetate.
DB13365
The risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Calcium acetate.
DB13590
The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Calcium acetate.
DB13800
The risk or severity of adverse effects can be increased when Calcium levulinate is combined with Calcium acetate.
DB14577
The risk or severity of adverse effects can be increased when Calcium cation is combined with Calcium acetate.
DB14684
The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Calcium acetate.
DB00390
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.
DB00511
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
DB01078
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Deslanoside.
DB01092
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Ouabain.
DB01396
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.
DB12843
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Oleandrin.
DB13240
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Cymarin.
DB13307
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Proscillaridin.
DB13401
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Metildigoxin.
DB13467
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Lanatoside C.
DB13537
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Gitoformate.
DB13691
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.
DB13756
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Peruvoside.
DB09267
The serum concentration of Strontium ranelate can be decreased when it is combined with Calcium acetate.
DB00254
The serum concentration of Doxycycline can be decreased when it is combined with Calcium acetate.
DB00256
The serum concentration of Lymecycline can be decreased when it is combined with Calcium acetate.
DB00453
The serum concentration of Clomocycline can be decreased when it is combined with Calcium acetate.
DB00595
The serum concentration of Oxytetracycline can be decreased when it is combined with Calcium acetate.
DB00618
The serum concentration of Demeclocycline can be decreased when it is combined with Calcium acetate.
DB00759
The serum concentration of Tetracycline can be decreased when it is combined with Calcium acetate.
DB00931
The serum concentration of Metacycline can be decreased when it is combined with Calcium acetate.
DB01017
The serum concentration of Minocycline can be decreased when it is combined with Calcium acetate.
DB12035
The serum concentration of Sarecycline can be decreased when it is combined with Calcium acetate.
DB12455
The serum concentration of Omadacycline can be decreased when it is combined with Calcium acetate.
DB13264
The serum concentration of Penimepicycline can be decreased when it is combined with Calcium acetate.
DB00232
Methyclothiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00310
Chlorthalidone may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00436
Bendroflumethiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00524
Metolazone may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00562
Benzthiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00774
Hydroflumethiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00808
Indapamide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00880
Chlorothiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB00999
Hydrochlorothiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB01021
Trichlormethiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB01324
Polythiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB01325
Quinethazone may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB13532
Cyclopenthiazide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB13989
Epitizide may decrease the excretion rate of Calcium acetate which could result in a higher serum level.
DB06824
The serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium acetate.
DB00136
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Calcitriol.
DB00146
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Calcifediol.
DB00153
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Ergocalciferol.
DB00169
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Cholecalciferol.
DB00910
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Paricalcitol.
DB01070
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Dihydrotachysterol.
DB01436
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Alfacalcidol.
DB02300
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Calcipotriol.
DB04258
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Seocalcitol.
DB04796
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Inecalcitol.
DB04891
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Becocalcidiol.
DB05295
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Eldecalcitol.
DB06117
The risk or severity of adverse effects can be increased when Calcium acetate is combined with 1alpha,24S-Dihydroxyvitamin D2.
DB06194
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Elocalcitol.
DB06272
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Maxacalcitol.
DB06410
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Doxercalciferol.
DB11094
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Vitamin D.
DB13097
The risk or severity of adverse effects can be increased when Calcium acetate is combined with 1alpha-Hydroxyvitamin D5.
DB13689
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Tacalcitol.
DB00513
The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Calcium acetate.
DB00270
The therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium acetate.
DB00343
The therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium acetate.
DB00347
The therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium acetate.
DB00381
The therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium acetate.
DB00393
The therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium acetate.
DB00401
The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium acetate.
DB00528
The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium acetate.
DB00555
The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium acetate.
DB00568
The therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium acetate.
DB00593
The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium acetate.
DB00622
The therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium acetate.
DB00653
The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Calcium acetate.
DB00661
The therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium acetate.
DB00836
The therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium acetate.
DB00909
The therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium acetate.
DB01023
The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium acetate.
DB01054
The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium acetate.
DB01074
The therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium acetate.
DB01115
The therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium acetate.
DB01118
The therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium acetate.
DB01136
The therapeutic efficacy of Carvedilol can be decreased when used in combination with Calcium acetate.
DB01244
The therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium acetate.
DB01388
The therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium acetate.
DB04743
The therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium acetate.
DB04825
The therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium acetate.
DB04838
The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium acetate.
DB04841
The therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium acetate.
DB04842
The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium acetate.
DB04920
The therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium acetate.
DB05246
The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium acetate.
DB05885
The therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium acetate.
DB06152
The therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium acetate.
DB06283
The therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium acetate.
DB06446
The therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium acetate.
DB06694
The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium acetate.
DB06712
The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium acetate.
DB07615
The therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium acetate.
DB08162
The therapeutic efficacy of Fasudil can be decreased when used in combination with Calcium acetate.
DB08838
The therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium acetate.
DB08980
The therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium acetate.
DB08992
The therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium acetate.
DB09089
The therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium acetate.
DB09090
The therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium acetate.
DB09216
The therapeutic efficacy of Tolfenamic acid can be decreased when used in combination with Calcium acetate.
DB09227
The therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium acetate.
DB09229
The therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium acetate.
DB09230
The therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium acetate.
DB09231
The therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium acetate.
DB09232
The therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium acetate.
DB09234
The therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium acetate.
DB09235
The therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium acetate.
DB09236
The therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium acetate.
DB09238
The therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium acetate.
DB09239
The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium acetate.
DB09240
The therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium acetate.
DB11960
The therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium acetate.
DB12092
The therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium acetate.
DB12093
The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium acetate.
DB12131
The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium acetate.
DB12923
The therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium acetate.
DB13488
The therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium acetate.
DB13500
The therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium acetate.
DB13725
The therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium acetate.
DB13766
The therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium acetate.
DB13791
The therapeutic efficacy of Penfluridol can be decreased when used in combination with Calcium acetate.
DB13835
The therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium acetate.
DB13950
The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium acetate.
DB13961
The therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium acetate.
DB14063
The therapeutic efficacy of Dexverapamil can be decreased when used in combination with Calcium acetate.
DB14064
The therapeutic efficacy of Emopamil can be decreased when used in combination with Calcium acetate.
DB14065
The therapeutic efficacy of Lomerizine can be decreased when used in combination with Calcium acetate.
DB14066
The therapeutic efficacy of Tetrandrine can be decreased when used in combination with Calcium acetate.
DB14068
The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Calcium acetate.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium acetate.
DB00279
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium acetate.
DB00451
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium acetate.
DB01583
The therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium acetate.
DB03604
The therapeutic efficacy of Tiratricol can be decreased when used in combination with Calcium acetate.
DB09100
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium acetate.
DB00282
The serum concentration of Pamidronic acid can be decreased when it is combined with Calcium acetate.
DB00399
The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium acetate.
DB00630
The serum concentration of Alendronic acid can be decreased when it is combined with Calcium acetate.
DB00710
The serum concentration of Ibandronate can be decreased when it is combined with Calcium acetate.
DB00720
The serum concentration of Clodronic acid can be decreased when it is combined with Calcium acetate.
DB00884
The serum concentration of Risedronic acid can be decreased when it is combined with Calcium acetate.
DB01077
The serum concentration of Etidronic acid can be decreased when it is combined with Calcium acetate.
DB01133
The serum concentration of Tiludronic acid can be decreased when it is combined with Calcium acetate.
DB06255
The serum concentration of Incadronic acid can be decreased when it is combined with Calcium acetate.
DB02369
Calcium acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB02423
Calcium acetate can cause a decrease in the absorption of Thiopyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB02552
Calcium acetate can cause a decrease in the absorption of Geranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB04160
Calcium acetate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB05143
Calcium acetate can cause a decrease in the absorption of OXI-4503 resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB07841
Calcium acetate can cause a decrease in the absorption of Geranylgeranyl diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09147
Calcium acetate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09413
Calcium acetate can cause a decrease in the absorption of Monopotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09414
Calcium acetate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09449
Calcium acetate can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11493
Calcium acetate can cause a decrease in the absorption of Sodium tripolyphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14481
Calcium acetate can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14523
Calcium acetate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09139
Calcium acetate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
DB00058
Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium acetate.
DB00170
Menadione may increase the thrombogenic activities of Calcium acetate.
DB00302
Tranexamic acid may increase the thrombogenic activities of Calcium acetate.
DB06692
Aprotinin may increase the thrombogenic activities of Calcium acetate.
DB11091
Hydrogen peroxide may increase the thrombogenic activities of Calcium acetate.
DB13244
Aminomethylbenzoic acid may increase the thrombogenic activities of Calcium acetate.
DB13729
Camostat may increase the thrombogenic activities of Calcium acetate.
DB00009
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Alteplase.
DB00013
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Urokinase.
DB00015
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Reteplase.
DB00029
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Anistreplase.
DB00031
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Tenecteplase.
DB00054
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Abciximab.
DB00055
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Drotrecogin alfa.
DB00086
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Streptokinase.
DB00266
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dicoumarol.
DB00278
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Argatroban.
DB00569
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Fondaparinux.
DB01088
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Iloprost.
DB04925
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Desmoteplase.
DB04932
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Defibrotide.
DB05099
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ancrod.
DB05254
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Fibrinolysin.
DB06271
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Sulodexide.
DB06543
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Astaxanthin.
DB06679
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Amediplase.
DB06754
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Danaparoid.
DB06779
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dalteparin.
DB06822
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Tinzaparin.
DB09075
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Edoxaban.
DB11312
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Protein C.
DB12726
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Monteplase.
DB13199
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Brinase.
DB13646
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Saruplase.
DB00001
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Lepirudin.
DB00006
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Bivalirudin.
DB00407
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ardeparin.
DB00498
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Phenindione.
DB00682
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Warfarin.
DB00686
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Pentosan polysulfate.
DB00945
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Acetylsalicylic acid.
DB00946
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Phenprocoumon.
DB00975
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dipyridamole.
DB01109
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Heparin.
DB01225
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Enoxaparin.
DB01240
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Epoprostenol.
DB01418
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Acenocoumarol.
DB03410
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with 4-hydroxycoumarin.
DB04665
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Coumarin.
DB04898
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ximelagatran.
DB05229
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Beraprost.
DB06209
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Prasugrel.
DB06228
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Rivaroxaban.
DB06406
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Idraparinux.
DB06441
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Cangrelor.
DB06605
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Apixaban.
DB06635
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Otamixaban.
DB06695
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dabigatran etexilate.
DB07767
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ferulic acid.
DB08496
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with (R)-warfarin.
DB08794
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ethyl biscoumacetate.
DB08813
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Nadroparin.
DB08814
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Triflusal.
DB08816
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ticagrelor.
DB08994
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Ditazole.
DB09030
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Vorapaxar.
DB09125
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Potassium citrate.
DB09154
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Sodium citrate.
DB09255
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dextran.
DB09258
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Bemiparin.
DB09260
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Parnaparin.
DB11095
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Desirudin.
DB11154
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Zinc citrate.
DB11166
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Antithrombin Alfa.
DB11598
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Antithrombin III human.
DB11984
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Letaxaban.
DB12289
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Darexaban.
DB12364
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Betrixaban.
DB12598
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Nafamostat.
DB12831
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Gabexate.
DB13136
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Fluindione.
DB13149
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Protein S human.
DB13275
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Clorindione.
DB13347
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Diphenadione.
DB13451
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Tioclomarol.
DB13616
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Melagatran.
DB14055
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with (S)-Warfarin.
DB14094
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Tocopherylquinone.
DB14598
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Edetate calcium disodium anhydrous.
DB14726
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dabigatran.
DB06294
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Semuloparin.
DB13124
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Troxerutin.
DB00974
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Edetic acid.
DB09259
The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Reviparin.
DB00187
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium acetate.
DB00195
The therapeutic efficacy of Betaxolol can be decreased when used in combination with Calcium acetate.
DB00264
The therapeutic efficacy of Metoprolol can be decreased when used in combination with Calcium acetate.
DB00335
The therapeutic efficacy of Atenolol can be decreased when used in combination with Calcium acetate.
DB00373
The therapeutic efficacy of Timolol can be decreased when used in combination with Calcium acetate.
DB00489
The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium acetate.
DB00571
The therapeutic efficacy of Propranolol can be decreased when used in combination with Calcium acetate.
DB00598
The therapeutic efficacy of Labetalol can be decreased when used in combination with Calcium acetate.
DB00612
The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Calcium acetate.
DB00866
The therapeutic efficacy of Alprenolol can be decreased when used in combination with Calcium acetate.
DB00960
The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium acetate.
DB01182
The therapeutic efficacy of Propafenone can be decreased when used in combination with Calcium acetate.
DB01193
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium acetate.
DB01203
The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium acetate.
DB01295
The therapeutic efficacy of Bevantolol can be decreased when used in combination with Calcium acetate.
DB01297
The therapeutic efficacy of Practolol can be decreased when used in combination with Calcium acetate.
DB01359
The therapeutic efficacy of Penbutolol can be decreased when used in combination with Calcium acetate.
DB01580
The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Calcium acetate.
DB03322
The therapeutic efficacy of Dexpropranolol can be decreased when used in combination with Calcium acetate.
DB04846
The therapeutic efficacy of Celiprolol can be decreased when used in combination with Calcium acetate.
DB04861
The therapeutic efficacy of Nebivolol can be decreased when used in combination with Calcium acetate.
DB06726
The therapeutic efficacy of Bufuralol can be decreased when used in combination with Calcium acetate.
DB08807
The therapeutic efficacy of Bopindolol can be decreased when used in combination with Calcium acetate.
DB08808
The therapeutic efficacy of Bupranolol can be decreased when used in combination with Calcium acetate.
DB08952
The therapeutic efficacy of Indenolol can be decreased when used in combination with Calcium acetate.
DB09204
The therapeutic efficacy of Arotinolol can be decreased when used in combination with Calcium acetate.
DB09351
The therapeutic efficacy of Levobetaxolol can be decreased when used in combination with Calcium acetate.
DB11770
The therapeutic efficacy of Talinolol can be decreased when used in combination with Calcium acetate.
DB11785
The therapeutic efficacy of Anisodamine can be decreased when used in combination with Calcium acetate.
DB12752
The therapeutic efficacy of Bucindolol can be decreased when used in combination with Calcium acetate.
DB13443
The therapeutic efficacy of Esatenolol can be decreased when used in combination with Calcium acetate.
DB13508
The therapeutic efficacy of Cloranolol can be decreased when used in combination with Calcium acetate.
DB13530
The therapeutic efficacy of Mepindolol can be decreased when used in combination with Calcium acetate.
DB13757
The therapeutic efficacy of Epanolol can be decreased when used in combination with Calcium acetate.
DB13775
The therapeutic efficacy of Tertatolol can be decreased when used in combination with Calcium acetate.
DB12212
The therapeutic efficacy of Landiolol can be decreased when used in combination with Calcium acetate.
DB00688
Calcium acetate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.

序列

实验性质

Melting Point
> 160 °C

外部标识符

resource：Drugs Product Database (DPD)
identifier：4810
resource：ChEBI
identifier：3310
resource：PubChem Compound
identifier：6116
resource：PubChem Substance
identifier：46507985
resource：KEGG Drug
identifier：D00931
resource：ChemSpider
identifier：5890
resource：PharmGKB
identifier：PA164746897
resource：Wikipedia
identifier：Calcium_acetate
resource：ChEMBL
identifier：CHEMBL1200800
resource：RxCUI
identifier：214342

外部链接

Drugs.com
http://www.drugs.com/cdi/calcium-acetate.html

路径

目标

id:BE0004815
name:Phosphate
organism:Humans
action:binder
Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5.
Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9.
Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20.
Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14.
known-action:yes

酶

载体

运输工具

药物反应

效应

不良反应